Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada
Objectives The similarity in retention of tumour necrosis factor inhibitors (TNFi) and tofacitinib (TOFA) was previously reported separately by the Ontario Best Practices Research Initiative and the Quebec cohort Rhumadata. However, because of small sample sizes in each registry, we aimed to confirm...
Main Authors: | Mohammad Movahedi, Angela Cesta, Claire Bombardier, Edward C Keystone, Denis Choquette, Xiuying Li, Louis Coupal, OBRI Investigators |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-03-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/13/3/e063198.full |
Similar Items
-
Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort.
by: Mohammad Movahedi, et al.
Published: (2022-01-01) -
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
by: Denis Choquette, et al.
Published: (2019-06-01) -
Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative
by: Xiuying Li, et al.
Published: (2022-11-01) -
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
by: Francesca Romana Spinelli, et al.
Published: (2023-09-01) -
Cardiovascular Risk Factors and the Risk of Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results From the Ontario Best Practices Research Initiative
by: Samar Aboulenain, et al.
Published: (2023-12-01)